Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten-day decitabine regimen., However, functional c...

Descripción completa

Detalles Bibliográficos
Autores principales: Bories, Pierre, Prade, Naïs, Lagarde, Stéphanie, Cabarrou, Bastien, Largeaud, Laetitia, Plenecassagnes, Julien, Luquet, Isabelle, De Mas, Véronique, Filleron, Thomas, Cassou, Manon, Sarry, Audrey, Fornecker, Luc-Matthieu, Simand, Célestine, Bertoli, Sarah, Recher, Christian, Delabesse, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529302/
https://www.ncbi.nlm.nih.gov/pubmed/33001991
http://dx.doi.org/10.1371/journal.pone.0238795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529302/
https://www.ncbi.nlm.nih.gov/pubmed/33001991
http://dx.doi.org/10.1371/journal.pone.0238795

Ejemplares similares